165 related articles for article (PubMed ID: 38234720)
1. Identification of a Musashi2 translocation as a novel oncogene in myeloid leukemia.
Spinler K; Hamilton M; Bajaj J; Shima Y; Diaz E; Kritzik M; Reya T
bioRxiv; 2023 Dec; ():. PubMed ID: 38234720
[TBL] [Abstract][Full Text] [Related]
2. A novel gene, MSI2, encoding a putative RNA-binding protein is recurrently rearranged at disease progression of chronic myeloid leukemia and forms a fusion gene with HOXA9 as a result of the cryptic t(7;17)(p15;q23).
Barbouti A; Höglund M; Johansson B; Lassen C; Nilsson PG; Hagemeijer A; Mitelman F; Fioretos T
Cancer Res; 2003 Mar; 63(6):1202-6. PubMed ID: 12649177
[TBL] [Abstract][Full Text] [Related]
3. Blast crisis Ph+ chronic myeloid leukemia with NUP98/HOXA13 up-regulating MSI2.
Di Giacomo D; Pierini V; Barba G; Ceccarelli V; Vecchini A; Mecucci C
Mol Cytogenet; 2014; 7():42. PubMed ID: 24971156
[TBL] [Abstract][Full Text] [Related]
4. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.
Dash AB; Williams IR; Kutok JL; Tomasson MH; Anastasiadou E; Lindahl K; Li S; Van Etten RA; Borrow J; Housman D; Druker B; Gilliland DG
Proc Natl Acad Sci U S A; 2002 May; 99(11):7622-7. PubMed ID: 12032333
[TBL] [Abstract][Full Text] [Related]
5. Regulation of myeloid leukaemia by the cell-fate determinant Musashi.
Ito T; Kwon HY; Zimdahl B; Congdon KL; Blum J; Lento WE; Zhao C; Lagoo A; Gerrard G; Foroni L; Goldman J; Goh H; Kim SH; Kim DW; Chuah C; Oehler VG; Radich JP; Jordan CT; Reya T
Nature; 2010 Aug; 466(7307):765-8. PubMed ID: 20639863
[TBL] [Abstract][Full Text] [Related]
6. Aggressive myeloid leukemia formation is directed by the Musashi 2/Numb pathway.
Griner LN; Reuther GW
Cancer Biol Ther; 2010 Nov; 10(10):979-82. PubMed ID: 21084860
[TBL] [Abstract][Full Text] [Related]
7.
Negi V; Vishwakarma BA; Chu S; Oakley K; Han Y; Bhatia R; Du Y
Oncotarget; 2017 Nov; 8(58):98853-98864. PubMed ID: 29228732
[TBL] [Abstract][Full Text] [Related]
8. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system.
Mayotte N; Roy DC; Yao J; Kroon E; Sauvageau G
Blood; 2002 Dec; 100(12):4177-84. PubMed ID: 12393433
[TBL] [Abstract][Full Text] [Related]
10. Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia.
Hattori A; Tsunoda M; Konuma T; Kobayashi M; Nagy T; Glushka J; Tayyari F; McSkimming D; Kannan N; Tojo A; Edison AS; Ito T
Nature; 2017 May; 545(7655):500-504. PubMed ID: 28514443
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity in expression of the bcr-abl fusion transcript in CML blast crisis.
Andrews DF; Collins SJ
Leukemia; 1987 Oct; 1(10):718-24. PubMed ID: 3312834
[TBL] [Abstract][Full Text] [Related]
12. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
[TBL] [Abstract][Full Text] [Related]
13. Chronic myeloid leukemia stem cells.
Jamieson CH
Hematology Am Soc Hematol Educ Program; 2008; ():436-42. PubMed ID: 19074122
[TBL] [Abstract][Full Text] [Related]
14. Does HOXA9 Gene Expression in Egyptian Chronic Myelogenous Leukemia Patients Affect Disease Progression? A Retrospective Cohort Study.
Mohamad Ismail MM; Manar MM
Turk J Haematol; 2013 Dec; 30(4):359-65. PubMed ID: 24385825
[TBL] [Abstract][Full Text] [Related]
15. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
Mak DH; Schober WD; Chen W; Konopleva M; Cortes J; Kantarjian HM; Andreeff M; Carter BZ
Mol Cancer Ther; 2009 Sep; 8(9):2509-16. PubMed ID: 19723894
[TBL] [Abstract][Full Text] [Related]
16. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
[TBL] [Abstract][Full Text] [Related]
17. RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.
Roche-Lestienne C; Deluche L; Corm S; Tigaud I; Joha S; Philippe N; Geffroy S; Laï JL; Nicolini FE; Preudhomme C;
Blood; 2008 Apr; 111(7):3735-41. PubMed ID: 18202228
[TBL] [Abstract][Full Text] [Related]
18. Co-expression of HoxA9 and bcr-abl genes in chronic myeloid leukemia.
Tedeschi FA; Cardozo MA; Valentini R; Zalazar FE
Leuk Lymphoma; 2010 May; 51(5):892-6. PubMed ID: 20141430
[TBL] [Abstract][Full Text] [Related]
19. Expression of the NUP98/HOXA9 fusion transcript in the blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia with t(7;11)(p15;p15).
Yamamoto K; Nakamura Y; Saito K; Furusawa S
Br J Haematol; 2000 May; 109(2):423-6. PubMed ID: 10848835
[TBL] [Abstract][Full Text] [Related]
20. Graft-versus-leukemia (GVL) against mouse blast-crisis chronic myelogenous leukemia (BC-CML) and chronic-phase chronic myelogenous leukemia (CP-CML): shared mechanisms of T cell killing, but programmed death ligands render CP-CML and not BC-CML GVL resistant.
Matte-Martone C; Venkatesan S; Tan HS; Athanasiadis I; Chang J; Pavisic J; Shlomchik WD
J Immunol; 2011 Aug; 187(4):1653-63. PubMed ID: 21768400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
